Artwork

Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Early-Stage Non–Small Cell Lung Cancer: Answers to Frequently Asked Questions

5:58
 
Distribuie
 

Manage episode 422444667 series 1163940
Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
In this video, Dr. Jamie E. Chaft, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Leveraging the Growing Arsenal of Therapies for Early-Stage Non–Small Cell Lung Cancer (NSCLC), chaired by Dr. Helena Yu. Dr. Chaft shares insights into emerging roles of measurable residual disease (MRD) in lung cancer, the significance of the recent approval of alectinib for ALK-positive disease, treatment considerations for older versus younger patients, important research updates at the American Society of Clinical Oncology (ASCO) Annual Meeting, and more! Interested in completing this activity and earning FREE CME/NCPD credit? Click here: https://bit.ly/4aWBk33
  continue reading

388 episoade

Artwork
iconDistribuie
 
Manage episode 422444667 series 1163940
Content provided by Oncology Data Advisor® and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Oncology Data Advisor® and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
In this video, Dr. Jamie E. Chaft, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Leveraging the Growing Arsenal of Therapies for Early-Stage Non–Small Cell Lung Cancer (NSCLC), chaired by Dr. Helena Yu. Dr. Chaft shares insights into emerging roles of measurable residual disease (MRD) in lung cancer, the significance of the recent approval of alectinib for ALK-positive disease, treatment considerations for older versus younger patients, important research updates at the American Society of Clinical Oncology (ASCO) Annual Meeting, and more! Interested in completing this activity and earning FREE CME/NCPD credit? Click here: https://bit.ly/4aWBk33
  continue reading

388 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință